{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:11Z","timestamp":1787242631204,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To provide an overview of the association between angiotensin II receptor blocker (ARB) use and cognitive outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>ARBs have previously shown greater neuroprotection compared to other anti-hypertensive classes. The benefits are primarily attributed to the ARB\u2019s effect on modulating the renin-angiotensin system via inhibiting the Ang II\/AT1R pathway and activating the Ang II\/AT2R, Ang IV\/AT4R, and Ang-(1\u20137)\/MasR pathways. These interactions are associated with pleiotropic neurocognitive benefits, including reduced \u03b2-amyloid accumulation and abnormal hyperphosphorylation of tau, ameliorated brain hypo-fusion, reduced neuroinflammation and synaptic dysfunction, better neurotoxin clearing, and blood\u2013brain barrier function restoration. While ACEis also inhibit AT1R, they simultaneously lower Ang II and block the Ang II\/AT2R and Ang IV\/AT4R pathways that counterbalance the potential benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>ARBs may be considered an adjunctive approach for neuroprotection. This preliminary evidence, coupled with their underlying mechanistic pathways, emphasizes the need for future long-term randomized trials to yield more definitive results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11906-023-01266-0","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:02:23Z","timestamp":1695272543000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Angiotensin Receptor Blockers and Cognition: a Scoping Review"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-8686","authenticated-orcid":false,"given":"Zhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne G.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.60.2.185","volume":"60","author":"DA Evans","year":"2003","unstructured":"Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185\u20139.","journal-title":"Arch Neurol"},{"key":"1266_CR2","unstructured":"World Health Organization (WHO). Dementia -key fact. March 2023. Accessed from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia#:~:text=Key%20facts,injuries%20that%20affect%20the%20brain. 20 Apr 2023."},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788\u201394.","journal-title":"Lancet Neurol"},{"key":"1266_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13311-019-00747-y","volume":"16","author":"N Wahidi","year":"2019","unstructured":"Wahidi N, Lerner AJ. Blood pressure control and protection of the aging brain. Neurotherapeutics. 2019;16:569\u201379.","journal-title":"Neurotherapeutics"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41581-021-00430-6","volume":"17","author":"Z Ungvari","year":"2021","unstructured":"Ungvari Z, Toth P, Tarantini S, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021;17:639\u201354.","journal-title":"Nat Rev Nephrol"},{"key":"1266_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ana.23554","volume":"71","author":"Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI, Group SS","year":"2012","unstructured":"Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI, Group SS. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol. 2012;71:825\u201333.","journal-title":"Ann Neurol"},{"key":"1266_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1212\/01.WNL.0000068023.14587.06","volume":"60","author":"V Novak","year":"2003","unstructured":"Novak V, Chowdhary A, Farrar B, et al. Altered cerebral vasoregulation in hypertension and stroke. Neurology. 2003;60:1657\u201363.","journal-title":"Neurology"},{"key":"1266_CR8","doi-asserted-by":"crossref","unstructured":"Eglit GML, Weigand AJ, Nation DA, Bondi MW, Bangen KJ. Hypertension and Alzheimer\u2019s disease: indirect effects through circle of Willis atherosclerosis. Brain Commun. 2020;2:fcaa114.","DOI":"10.1093\/braincomms\/fcaa114"},{"key":"1266_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"\u2022 Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553\u201361. This randomized clinical trial demonstrated that intensive blood pressure control significantly reduced the risk of mild cognitive impairment and the combined rate of mild cognitive impairment or probable dementia.","journal-title":"JAMA"},{"key":"1266_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","volume":"31","author":"N Levi Marpillat","year":"2013","unstructured":"Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31:1073\u201382.","journal-title":"J Hypertens"},{"key":"1266_CR11","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1093\/eurheartj\/ehac584","volume":"43","author":"R Peters","year":"2022","unstructured":"Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43:4980\u201390.","journal-title":"Eur Heart J"},{"key":"1266_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1179\/016164103101201986","volume":"25","author":"I Skoog","year":"2003","unstructured":"Skoog I, Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer\u2019s disease. Neurol Res. 2003;25:675\u201380.","journal-title":"Neurol Res"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1212\/WNL.0000000000008732","volume":"94","author":"R Peters","year":"2020","unstructured":"Peters R, Yasar S, Anderson CS, et al. Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology. 2020;94:e267\u201381.","journal-title":"Neurology"},{"key":"1266_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61\u201370.","journal-title":"Lancet Neurol"},{"issue":"1386\u20131395","key":"1266_CR15","volume":"22","author":"M den Brok","year":"2021","unstructured":"den Brok M, van Dalen JW, Abdulrahman H, et al. Antihypertensive medication classes and the risk of dementia: a systematic review and network meta-analysis. J Am Med Dir Assoc. 2021;22(1386\u20131395): e15.","journal-title":"J Am Med Dir Assoc"},{"key":"1266_CR16","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1161\/HYPERTENSIONAHA.122.19859","volume":"79","author":"S Yasar","year":"2022","unstructured":"Yasar S, Wharton W. Angiotensin receptor blockers and dementia prevention: do not RAS to a conclusion yet. Hypertension. 2022;79:2170\u20132.","journal-title":"Hypertension"},{"key":"1266_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160:1273\u201392.","journal-title":"Br J Pharmacol"},{"key":"1266_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(07)70077-7","volume":"6","author":"PG Kehoe","year":"2007","unstructured":"Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer\u2019s disease? Lancet Neurol. 2007;6:373\u20138.","journal-title":"Lancet Neurol"},{"key":"1266_CR19","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s12035-015-9260-9","volume":"53","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhang YD, Zhou JS, et al. Angiotensin-(1\u20137) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer\u2019s disease. Mol Neurobiol. 2016;53:2489\u201397.","journal-title":"Mol Neurobiol"},{"key":"1266_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","volume":"369","author":"RE Schmieder","year":"2007","unstructured":"Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208\u201319.","journal-title":"Lancet"},{"key":"1266_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.expneurol.2009.09.012","volume":"223","author":"JW Wright","year":"2010","unstructured":"Wright JW, Harding JW. The brain RAS and Alzheimer\u2019s disease. Exp Neurol. 2010;223:326\u201333.","journal-title":"Exp Neurol"},{"key":"1266_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ajh\/hpu161","volume":"28","author":"I Hajjar","year":"2015","unstructured":"Hajjar I, Hart M, Mack W, Lipsitz LA. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. Am J Hypertens. 2015;28:319\u201325.","journal-title":"Am J Hypertens"},{"key":"1266_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1586\/ern.09.89","volume":"9","author":"A Fournier","year":"2009","unstructured":"Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9:1413\u201331.","journal-title":"Expert Rev Neurother"},{"key":"1266_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s13311-019-00723-6","volume":"16","author":"HJ Drews","year":"2019","unstructured":"Drews HJ, Yenkoyan K, Lourhmati A, et al. Intranasal losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats. Neurotherapeutics. 2019;16:725\u201340.","journal-title":"Neurotherapeutics"},{"key":"1266_CR25","doi-asserted-by":"crossref","unstructured":"Garcia-Lluch G, Pena-Bautista C, Royo LM, Baquero M, Canada-Martinez AJ, Chafer-Pericas C. Angiotensin II receptor blockers reduce tau\/Ass42 ratio: a cerebrospinal fluid biomarkers\u2019 case-control study. Pharmaceutics. 2023;15.","DOI":"10.3390\/pharmaceutics15030924"},{"key":"1266_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.dadm.2016.02.007","volume":"2","author":"L Glodzik","year":"2016","unstructured":"Glodzik L, Rusinek H, Kamer A, et al. Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimers Dement (Amst). 2016;2:95\u2013104.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1266_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","volume":"69","author":"I Hajjar","year":"2012","unstructured":"Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol. 2012;69:1632\u20138.","journal-title":"Arch Neurol"},{"key":"1266_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Ouk M, Wu CY, Rabin JS et al. Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging. 2021;100:22\u201331. This cohort study of 142 cognitively normal older adults found that ARB versus ACE-I use was associated with slower \u03b2-amyloid accumulation in the cortex.","DOI":"10.1016\/j.neurobiolaging.2020.12.011"},{"key":"1266_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JAD-190011","volume":"70","author":"W Wharton","year":"2019","unstructured":"Wharton W, Zhao L, Steenland K, et al. Neurofibrillary tangles and conversion to mild cognitive impairment with certain antihypertensives. J Alzheimers Dis. 2019;70:153\u201361.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR30","doi-asserted-by":"crossref","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","DOI":"10.1056\/NEJMoa0801317"},{"key":"1266_CR31","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3233\/JAD-180943","volume":"68","author":"C Moran","year":"2019","unstructured":"Moran C, Xie K, Poh S, et al. Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time. J Alzheimers Dis. 2019;68:1479\u201388.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-2011-110347","volume":"26","author":"NM Davies","year":"2011","unstructured":"Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer\u2019s disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26:699\u2013708.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105515","volume":"166","author":"L Scotti","year":"2021","unstructured":"\u2022\u2022 Scotti L, Bassi L, Soranna D, et al. Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: a meta-analysis. Pharmacol Res. 2021;166: 105515. This recent meta-analysis found that ARB was superior to ACEi and other antihypertensives in reducing the risk of dementia.","journal-title":"Pharmacol Res"},{"key":"1266_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","volume":"10","author":"C Anderson","year":"2011","unstructured":"\u2022\u2022 Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10:43\u201353.\u00a0Two early randomized trials of people aged over 55 years old found no significant effect of RAS inhibitor antihypertensives on cognitive function and no differential effect between ARBs and ACEis over 4.7 years.","journal-title":"Lancet Neurol"},{"key":"1266_CR35","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.hjh.0000133730.47372.4c","volume":"22","author":"H Lithell","year":"2004","unstructured":"Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22:1605\u201312.","journal-title":"J Hypertens"},{"key":"1266_CR36","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.amjhyper.2005.02.013","volume":"18","author":"I Skoog","year":"2005","unstructured":"Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens. 2005;18:1052\u20139.","journal-title":"Am J Hypertens"},{"key":"1266_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","volume":"7","author":"HC Diener","year":"2008","unstructured":"Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875\u201384.","journal-title":"Lancet Neurol"},{"key":"1266_CR38","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1097\/HJH.0b013e328301a280","volume":"26","author":"O Hanon","year":"2008","unstructured":"Hanon O, Berrou JP, Negre-Pages L, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the observational study on cognitive function and systolic blood pressure reduction open-label study. J Hypertens. 2008;26:1642\u201350.","journal-title":"J Hypertens"},{"key":"1266_CR39","doi-asserted-by":"crossref","unstructured":"\u2022\u2022\u00a0Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465. This large-scale population-based cohort study using the administrative database of the US Veteran Affairs suggests a significant association between ARB use and reduced incidence and progression of AD and dementia compared with ACEis and other cardiovascular drugs.","DOI":"10.1136\/bmj.b5465"},{"key":"1266_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1253\/circj.CJ-12-0658","volume":"77","author":"CY Hsu","year":"2013","unstructured":"Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of Alzheimer\u2019s disease in hypertension population\u2013a nationwide cohort study. Circ J. 2013;77:405\u201310.","journal-title":"Circ J"},{"key":"1266_CR41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","volume":"81","author":"S Yasar","year":"2013","unstructured":"Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer disease: ginkgo evaluation of memory study. Neurology. 2013;81:896\u2013903.","journal-title":"Neurology"},{"key":"1266_CR42","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/HJH.0000000000000086","volume":"32","author":"WC Chiu","year":"2014","unstructured":"Chiu WC, Ho WC, Lin MH, et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32:938\u201347.","journal-title":"J Hypertens"},{"key":"1266_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bcp.12511","volume":"79","author":"KL Goh","year":"2015","unstructured":"Goh KL, Bhaskaran K, Minassian C, Evans SJ, Smeeth L, Douglas IJ. Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2015;79:337\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"1266_CR44","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ijcard.2016.06.215","volume":"220","author":"YC Kuan","year":"2016","unstructured":"Kuan YC, Huang KW, Yen DJ, Hu CJ, Lin CL, Kao CH. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. Int J Cardiol. 2016;220:462\u20136.","journal-title":"Int J Cardiol"},{"key":"1266_CR45","doi-asserted-by":"crossref","unstructured":"van Middelaar T, van Vught LA, Moll van Charante EP et al. Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens. 2017;35:2095\u20132101.","DOI":"10.1097\/HJH.0000000000001411"},{"key":"1266_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206705","volume":"13","author":"D Barthold","year":"2018","unstructured":"Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity. PLoS ONE. 2018;13: e0206705.","journal-title":"PLoS ONE"},{"key":"1266_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-190362","volume":"70","author":"J Bohlken","year":"2019","unstructured":"Bohlken J, Jacob L, Kostev K. The relationship between the use of antihypertensive drugs and the incidence of dementia in general practices in Germany. J Alzheimers Dis. 2019;70:91\u20137.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12252","volume":"3","author":"I Hajjar","year":"2020","unstructured":"Hajjar I, Okafor M, McDaniel D, et al. Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Netw Open. 2020;3: e2012252.","journal-title":"JAMA Netw Open"},{"key":"1266_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20680","volume":"5","author":"JB Cohen","year":"2022","unstructured":"Cohen JB, Marcum ZA, Zhang C, et al. Risk of mild cognitive impairment or probable dementia in new users of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors: a secondary analysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open. 2022;5: e2220680.","journal-title":"JAMA Netw Open"},{"key":"1266_CR50","doi-asserted-by":"publisher","first-page":"1137197","DOI":"10.3389\/fnagi.2023.1137197","volume":"15","author":"HW Lee","year":"2023","unstructured":"Lee HW, Kim S, Jo Y, Kim Y, Ye BS, Yu YM. Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer\u2019s disease: a nationwide population-based cohort study. Front Aging Neurosci. 2023;15:1137197.","journal-title":"Front Aging Neurosci"},{"key":"1266_CR51","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3233\/JAD-171119","volume":"62","author":"PG Kehoe","year":"2018","unstructured":"Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer\u2019s disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62:1443\u201366.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR52","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","volume":"27","author":"OA Abiodun","year":"2020","unstructured":"Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020;27:905\u201312.","journal-title":"Saudi J Biol Sci"},{"key":"1266_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000869","volume":"6","author":"M Balogh","year":"2021","unstructured":"Balogh M, Aguilar C, Nguyen NT, Shepherd AJ. Angiotensin receptors and neuropathic pain. Pain Rep. 2021;6: e869.","journal-title":"Pain Rep"},{"key":"1266_CR54","doi-asserted-by":"crossref","unstructured":"\u2022\u2022\u00a0Saavedra JM. Evidence to consider angiotensin II receptor blockers for the treatment of early Alzheimer\u2019s disease. Cell Mol Neurobiol. 2016;36:259\u201379. This is a comprehensive review paper illustrating the potential benefits of ARB use on preventing early Alzheimer\u2019s disease.","DOI":"10.1007\/s10571-015-0327-y"},{"key":"1266_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12012-022-09730-0","volume":"22","author":"H Wu","year":"2022","unstructured":"Wu H, Sun Q, Yuan S, et al. AT1 receptors: their actions from hypertension to cognitive impairment. Cardiovasc Toxicol. 2022;22:311\u201325.","journal-title":"Cardiovasc Toxicol"},{"key":"1266_CR56","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.188.4.661","volume":"188","author":"R Lucius","year":"1998","unstructured":"Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661\u201370.","journal-title":"J Exp Med"},{"key":"1266_CR57","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Ahmed HA, Ishrat T. The brain AT2R-a potential target for therapy in Alzheimer\u2019s disease and vascular cognitive impairment: a comprehensive review of clinical and experimental therapeutics. Mol Neurobiol. 2020;57:3458\u20133484. This is a comprehensive literature review summarizing the major causes, pathophysiology, and treatments of dementia as well as the potential impact of modulating the Ang II\/AT2R pathway via the RAS signalling on neurocognitive outcomes.","DOI":"10.1007\/s12035-020-01964-9"},{"key":"1266_CR58","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1476-5381.2010.01167.x","volume":"163","author":"M Horiuchi","year":"2011","unstructured":"Horiuchi M, Mogi M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol. 2011;163:1122\u201330.","journal-title":"Br J Pharmacol"},{"key":"1266_CR59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neubiorev.2018.05.005","volume":"92","author":"JK Ho","year":"2018","unstructured":"Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1\u20137): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209\u201325.","journal-title":"Neurosci Biobehav Rev"},{"key":"1266_CR60","doi-asserted-by":"crossref","unstructured":"\u2022\u2022\u00a0Wright JW, Harding JW. Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer\u2019s disease. J Alzheimers Dis. 2019;67:469\u2013480. This review paper summarized the existing evidence that supports the brain renin-angiotensin system as an effective drug target for improving neurocognitive outcomes.","DOI":"10.3233\/JAD-181035"},{"key":"1266_CR61","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1523\/JNEUROSCI.0329-17.2017","volume":"37","author":"J Royea","year":"2017","unstructured":"Royea J, Zhang L, Tong XK, Hamel E. Angiotensin IV receptors mediate the cognitive and cerebrovascular benefits of losartan in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2017;37:5562\u201373.","journal-title":"J Neurosci"},{"key":"1266_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","volume":"139","author":"CE Evans","year":"2020","unstructured":"Evans CE, Miners JS, Piva G, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer\u2019s disease. Acta Neuropathol. 2020;139:485\u2013502.","journal-title":"Acta Neuropathol"},{"key":"1266_CR63","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","volume":"8","author":"PG Kehoe","year":"2016","unstructured":"Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS. Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res Ther. 2016;8:50.","journal-title":"Alzheimers Res Ther"},{"key":"1266_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1567202613666160224124739","volume":"13","author":"T Jiang","year":"2016","unstructured":"Jiang T, Tan L, Gao Q, et al. Plasma angiotensin-(1\u20137) is a potential biomarker for Alzheimer\u2019s disease. Curr Neurovasc Res. 2016;13:96\u20139.","journal-title":"Curr Neurovasc Res"},{"key":"1266_CR65","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/00004872-200410000-00020","volume":"22","author":"DJ Campbell","year":"2004","unstructured":"Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens. 2004;22:1971\u20136.","journal-title":"J Hypertens"},{"key":"1266_CR66","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","volume":"14","author":"M Luque","year":"1996","unstructured":"Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1\u20137) in essential hypertension. J Hypertens. 1996;14:799\u2013805.","journal-title":"J Hypertens"},{"key":"1266_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","volume":"28","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15\u201321.","journal-title":"Am J Hypertens"},{"key":"1266_CR68","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653\u20139.","journal-title":"N Engl J Med"},{"key":"1266_CR69","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/jnr.23404","volume":"92","author":"S Liu","year":"2014","unstructured":"Liu S, Liu J, Miura Y, et al. Conversion of Abeta43 to Abeta40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme. J Neurosci Res. 2014;92:1178\u201386.","journal-title":"J Neurosci Res"},{"key":"1266_CR70","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","volume":"162","author":"F Forette","year":"2002","unstructured":"Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046\u201352.","journal-title":"Arch Intern Med"},{"key":"1266_CR71","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/HJH.0000000000003324","volume":"41","author":"JL Schroevers","year":"2023","unstructured":"Schroevers JL, Eggink E, Hoevenaar-Blom MP, et al. Antihypertensive medication classes and the risk of dementia over a decade of follow-up. J Hypertens. 2023;41:262\u201370.","journal-title":"J Hypertens"},{"key":"1266_CR72","doi-asserted-by":"crossref","unstructured":"\u2022\u2022\u00a0Marcum ZA, Cohen JB, Zhang C et al. Association of antihypertensives that stimulate vs inhibit types 2 and 4 angiotensin II receptors with cognitive impairment. JAMA Netw Open. 2022;5:e2145319. A post hoc analysis of the SPRINT randomized trial reported a significantly lower risk of cognitive impairment in participants taking AT2R\/AT4R stimulator anti-hypertensive medications compared with those taking AT2R\/AT4R inhibitor anti-hypertensive medications over a 5-year follow-up.","DOI":"10.1001\/jamanetworkopen.2021.45319"},{"key":"1266_CR73","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3233\/JAD-215393","volume":"86","author":"ZA Marcum","year":"2022","unstructured":"Marcum ZA, Li Y, Lee SJ, et al. Association of antihypertensives and cognitive impairment in long-term care residents. J Alzheimers Dis. 2022;86:1149\u201358.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR74","doi-asserted-by":"crossref","unstructured":"\u2022\u2022\u00a0Marcum ZA, Gabriel N, Bress AP, Hernandez I. Association of new use of antihypertensives that stimulate vs inhibit type 2 and 4 angiotensin II receptors with dementia among Medicare beneficiaries. JAMA Netw Open. 2023;6:e2249370. A large cohort study of Medicare beneficiaries reported lower risks of AD and related dementia with the use of AT2R\/AT4R stimulator anti-hypertensive medications compared with AT2R\/AT4R inhibitor anti-hypertensive medications over a 7-year follow-up.","DOI":"10.1001\/jamanetworkopen.2022.49370"},{"key":"1266_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1358\/dnp.2010.23.4.1437710","volume":"23","author":"RK Kaundal","year":"2010","unstructured":"Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 2010;23:241\u201356.","journal-title":"Drug News Perspect"},{"key":"1266_CR76","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/157015911798376325","volume":"9","author":"MT Heneka","year":"2011","unstructured":"Heneka MT, Reyes-Irisarri E, Hull M, Kummer MP. Impact and therapeutic potential of PPARs in Alzheimer\u2019s disease. Curr Neuropharmacol. 2011;9:643\u201350.","journal-title":"Curr Neuropharmacol"},{"key":"1266_CR77","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054\u20137.","journal-title":"Circulation"},{"key":"1266_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003707","volume":"18","author":"CH Liu","year":"2021","unstructured":"Liu CH, Sung PS, Li YR, et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: a population-based cohort study. PLoS Med. 2021;18: e1003707.","journal-title":"PLoS Med"},{"key":"1266_CR79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/npp.2010.225","volume":"36","author":"J Benicky","year":"2011","unstructured":"Benicky J, Sanchez-Lemus E, Honda M, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36:857\u201370.","journal-title":"Neuropsychopharmacology"},{"key":"1266_CR80","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10571-011-9754-6","volume":"32","author":"JM Saavedra","year":"2012","unstructured":"Saavedra JM, Angiotensin II. AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell Mol Neurobiol. 2012;32:667\u201381.","journal-title":"Cell Mol Neurobiol"},{"key":"1266_CR81","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1172\/JCI41709","volume":"120","author":"TV Lanz","year":"2010","unstructured":"Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest. 2010;120:2782\u201394.","journal-title":"J Clin Invest"},{"key":"1266_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104833","volume":"139","author":"PK Singh","year":"2020","unstructured":"Singh PK, Chen ZL, Ghosh D, Strickland S, Norris EH. Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer\u2019s patients. Neurobiol Dis. 2020;139: 104833.","journal-title":"Neurobiol Dis"},{"key":"1266_CR83","first-page":"884","volume":"115","author":"Q Wang","year":"2002","unstructured":"Wang Q, Wang J. Injection of bradykinin or cyclosporine A to hippocampus induces Alzheimer-like phosphorylation of tau and abnormal behavior in rats. Chin Med J (Engl). 2002;115:884\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"1266_CR84","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuroscience.2007.11.009","volume":"151","author":"RD Prediger","year":"2008","unstructured":"Prediger RD, Medeiros R, Pandolfo P, et al. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer\u2019s disease. Neuroscience. 2008;151:631\u201343.","journal-title":"Neuroscience"},{"key":"1266_CR85","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ajpath.2013.01.021","volume":"182","author":"GF Passos","year":"2013","unstructured":"Passos GF, Medeiros R, Cheng D, Vasilevko V, Laferla FM, Cribbs DH. The bradykinin B1 receptor regulates Abeta deposition and neuroinflammation in Tg-SwDI mice. Am J Pathol. 2013;182:1740\u20139.","journal-title":"Am J Pathol"},{"key":"1266_CR86","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1016\/j.peptides.2006.08.012","volume":"27","author":"LM Iores-Marcal","year":"2006","unstructured":"Iores-Marcal LM, Viel TA, Buck HS, et al. Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer\u2019s disease. Peptides. 2006;27:3363\u20139.","journal-title":"Peptides"},{"key":"1266_CR87","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jgs.13627","volume":"63","author":"W Wharton","year":"2015","unstructured":"Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I. Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Am Geriatr Soc. 2015;63:1749\u201356.","journal-title":"J Am Geriatr Soc"},{"key":"1266_CR88","doi-asserted-by":"crossref","unstructured":"Cuddy LK, Prokopenko D, Cunningham EP et al. Abeta-accelerated neurodegeneration caused by Alzheimer\u2019s-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice. Sci Transl Med. 2020;12.","DOI":"10.1126\/scitranslmed.aaz2541"},{"key":"1266_CR89","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Ouk M, Wu CY, Rabin JS et al. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease: the importance of blood-brain barrier penetration and APOE epsilon4 carrier status. Alzheimers Res Ther. 2021;13:43. This study suggests that the neuroprotective effects of ARBs may be mediated by their blood-brain barrier permeability and patients\u2019 APOE epsilon4 carrier status.","DOI":"10.1186\/s13195-021-00778-8"},{"key":"1266_CR90","doi-asserted-by":"crossref","unstructured":"Ho JK, Nation DA, Alzheimer\u2019s disease neuroimaging I. Memory is preserved in older adults taking AT1 receptor blockers. Alzheimers Res Ther. 2017;9:33.","DOI":"10.1186\/s13195-017-0255-9"},{"key":"1266_CR91","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2012-120763","volume":"32","author":"W Wharton","year":"2012","unstructured":"Wharton W, Stein JH, Korcarz C, et al. The effects of ramipril in individuals at risk for Alzheimer\u2019s disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32:147\u201356.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR92","doi-asserted-by":"crossref","unstructured":"\u2022Nation DA, Ho J, Yew B, Alzheimer\u2019s disease neuroimaging I. Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention. J Alzheimers Dis. 2016;50:779\u201389. A human study demonstrated an attenuation of age-related increases in cerebral \u03b2-amyloid retention and P-tau in ARB users.","DOI":"10.3233\/JAD-150487"},{"key":"1266_CR93","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1161\/HYPERTENSIONAHA.122.19378","volume":"79","author":"Z Deng","year":"2022","unstructured":"\u2022\u2022 Deng Z, Jiang J, Wang J, et al. Angiotensin receptor blockers are associated with a lower risk of progression from mild cognitive impairment to dementia. Hypertension. 2022;79:2159\u201369. This study using data of the Alzheimer\u2019s Disease Neuroimaging Initiative cohort reported that ARB users had a significantly lower annual risk of developing dementia compared with users of ACE-I, other- or no-antihypertensive users over a 3-year follow-up.","journal-title":"Hypertension"},{"key":"1266_CR94","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3233\/JAD-220439","volume":"89","author":"I Liampas","year":"2022","unstructured":"Liampas I, Hatzimanolis A, Siokas V, et al. Antihypertensive medication class and the risk of dementia and cognitive decline in older adults: a secondary analysis of the prospective HELIAD cohort. J Alzheimers Dis. 2022;89:709\u201319.","journal-title":"J Alzheimers Dis"},{"key":"1266_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2017.07.015","volume":"46","author":"M Stuhec","year":"2017","unstructured":"\u2022 Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: a systematic review. Eur Psychiatry. 2017;46:1\u201315. This meta-analysis of 15 randomized trials in older adults without initial dementia demonstrated a superiority of ARBs in improving cognitive function over other antihypertensive classes, despite their similar efficacy in lowering blood pressure as ARBs.","journal-title":"Eur Psychiatry"},{"key":"1266_CR96","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1212\/01.wnl.0000345062.86148.3f","volume":"72","author":"MD Haag","year":"2009","unstructured":"Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72:1727\u201334.","journal-title":"Neurology"},{"key":"1266_CR97","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875\u201386.","journal-title":"J Hypertens"},{"key":"1266_CR98","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","volume":"78","author":"R Chen","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78:591\u2013603.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-023-01266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-023-01266-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-023-01266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T07:21:31Z","timestamp":1705562491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-023-01266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s11906-023-01266-0","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"21 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}